PCSK9 and atherosclerosis: Interestingly, the meta-analysis of clinical outcomes of PCSK9 modulators (evolocumab, alirocumab, inclisiran) in patients with established atherosclerotic cardiovascular disease (ASCVD) indicated a reduction in the composite outcomes of MI, stroke, and cardiovascular death (relative risk RR 0.80, 95% CI 0.73–0.87) and MI, stroke, unstable angina (requiring revascularization), and cardiovascular death (RR 0.85, 95% CI 0.74–0.97).